The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia
Journal of Clinical Oncology (JCO) Podcast · Journals Online Team
February 21, 20128m 16s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels.